

**PROPOSED CLAIMS**

1. A method of treating hyperlipidemia in a hyperlipidemic comprising dosing the hyperlipidemic with an effective antihyperlipidemic amount of nicotinic acid once per day in the evening or at night, wherein said nicotinic acid is combined with at least one pharmaceutically acceptable carrier to form an oral solid dosage form.

2. A method, as set forth in Claim 1, wherein the hyperlipidemic is dosed with from about 250 milligrams to about 3000 milligrams of nicotinic acid.

3. A method as set forth in Claim 1 which causes little or no serious liver damage.

4. A method as set forth in Claim 1 wherein the release rate of said nicotinic acid is from about 2.0% per hour to about 25% per hour.

5. A method as set forth in Claim 6 wherein said nicotinic acid is prepared by formulating the active compound with from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose per 100 parts by weight of tablet.

6. A method, as set forth in Claim 1, wherein said nicotinic acid is dosed in the form of a sustained release tablet containing from about 1 to about 4 parts by weight of binder per 100 parts by weight of tablet.

7. A method, as set forth in Claim 6, wherein said binder is polyvinyl pyrrolidone.

8. A method, as set forth in Claim 1, wherein said nicotinic acid is dosed in the form of a sustained release tablet

comprising from about 0.5 to about 2.5 parts by weight of a lubricating agent per 100 parts by weight of tablet.

9. A method, as set forth in Claim 8, wherein said lubricating agent is selected from the group consisting of stearic acid and magnesium stearate.

13. A method of treating hyperlipidemia in a hyperlipidemic comprising dosing the hyperlipidemic with an effective antihyperlipidemic amount of a compound metabolized to nicotinic acid by the body and selected from the group consisting of nicotiny alcohol tartrate, d-glucitol hexanicotinate, aluminum nicotinate, and, 1-alpha-tocopheryl nicotinate, once per day in the evening or at night combined with at least one pharmaceutically acceptable carrier, to produce a reduction in total and LDL cholesterol, triglycerides and Lp(a), with a significant increase in HDL cholesterol.

14. A method of treating hyperlipidemia in a hyperlipidemic comprising dosing the hyperlipidemic with an effective antihyperlipidemic amount of a compound metabolized to nicotinic acid by the body and selected from the group consisting of nicotiny alcohol tartrate, d-glucitol hexanicotinate, aluminum nicotinate, and, 1-alpha-tocopheryl nicotinate, once per day in the evening or at night combined with at least one pharmaceutically acceptable carrier.